Klea Holding launches Klea Pharmaceuticals to target the healthcare market in the Middle East and Africa

Klea Holding has announced the creation of Klea Pharmaceuticals, a subsidiary focused on marketing pharmaceuticals in the Middle East and Africa. Despite economic disruptions caused by a regional conflict, the group is demonstrating its resilience, notably through Smart Salem, a network of digitized medical centers in the United Arab Emirates. Klea Pharmaceuticals is launching with a portfolio of 59 medications and will operate from Dubai. The UAE and Saudi Arabia are the initial target markets, with West Africa to follow.

Klea's strategy focuses on a high-growth regional pharmaceutical market. With an initial investment of AED 12.5 million, Klea Pharmaceuticals expects to achieve annual sales of over €50 million by 2032. Drug manufacturing will be outsourced through licensed international partnerships. This initiative supports Klea's diversification, strengthening its presence in the medical sector and its geographic expansion.